MK-677 vs. Ipamorelin
Samuel Sarmiento MD, MPH, MBA
MK-677 vs. Ipamorelin: Two Routes to the Ghrelin Receptor
by Dr. James Ross
Ipamorelin vs MK677
Both MK-677 (ibutamoren) and ipamorelin activate the ghrelin/GHSR-1a receptor to raise growth hormone (GH) and downstream IGF-1—but they differ in chemistry, delivery, selectivity, and secondary effects. MK-677 is an oral, non-peptide with a long half-life and notable sleep/appetite effects; ipamorelin is a short peptide with high pituitary selectivity and minimal off-axis endocrine spillover in studies. Preclinical and early clinical data suggest bone and body-composition benefits for both; MK-677 shows the clearest sleep architecture gains. All uses remain investigational.
Quick comparison
Feature
MK-677 (Ibutamoren)
Ipamorelin
Class
Non-peptide ghrelin receptor agonist
Pentapeptide ghrelin analog
Route
Oral (high bioavailability)
Parenteral (peptide)
Half-life / dosing
Long (~24 h in literature) → once daily in trials
Short → typically multiple daily injections in research settings
GH / IGF-1
Increases GH pulsatility and IGF-1; repeated human trials
Increases GH with high receptor selectivity; limited human data
Endocrine spillover
Early studies: no meaningful rise in cortisol/PRL; can raise appetite and water retention
Minimal ACTH/cortisol/PRL effects reported; highly selective
Sleep
Improves REM & slow-wave (stage 4) sleep; ↓ REM latency
Modest signals; less robust than MK-677
Metabolism
Can increase appetite; watch glucose/insulin in some cohorts
Stimulates insulin release in rodent pancreas models (preclinical)
Bone
↑ bone turnover markers; signals for density/strength support in older adults
Strong preclinical increases in bone formation/mineral content
Practical
Simple oral dosing; broader systemic effects (pro & con)
Targeted pituitary action; requires injections
Status
Investigational (GH deficiency/aging, fracture recovery, cachexia)
Investigational (GH deficiency, bone, GI motility research)
How they work (same lock, different keys)
Shared target: Both bind GHSR-1a, amplifying endogenous GH pulses (they don’t replace GH). That pulsatile pattern helps preserve physiologic signaling.
MK-677 is a small molecule that crosses membranes easily, giving once-daily coverage and CNS effects (appetite/sleep).
Ipamorelin is a highly selective peptide engineered to minimize activation of other pituitary axes (ACTH/cortisol, PRL, etc.), which is why it’s often highlighted for clean endocrine selectivity.
Evidence snapshots
Body composition & bone
MK-677 increased bone turnover markers in young men and in older adults, with trials reporting increases in IGF-1 and fat-free mass and signals toward functional gains post-hip fracture when paired with rehab (heterogeneous outcomes; edema and glucose shifts can occur) [3–5].
Ipamorelin produced robust bone effects in rats, including a four-fold rise in bone formation, higher mineral content, and reversal of glucocorticoid-induced suppression of bone formation [6–7].
Sleep & neurocognition
MK-677 repeatedly increased REM and stage-4 sleep and reduced REM latency in humans—effects that may contribute to perceived recovery and could relate to neuroprotective signals in preclinical work [8–9].
Glucose/insulin nuances
Rodent work suggests ipamorelin can potentiate insulin release via islet Ca2+ channels (species-specific; translational relevance still being established) [2].
MK-677 often increases appetite and, in some cohorts, can nudge fasting glucose/insulin—a trade-off to monitor in metabolic research.
When each might make sense (research framing)
Choose MK-677 when oral, once-daily dosing and sleep/appetite modulation are desired, or when IGF-1 elevation with sustained coverage is the goal.
Choose ipamorelin when tight pituitary selectivity and minimal off-axis endocrine activity are priorities, or when probing bone anabolism in controlled preclinical designs.
Combining them hasn’t been formally tested; any synergy remains speculative.
Safety & status (important)
Both agents are investigational. Most positive signals come from small trials or preclinical work; long-term efficacy/safety in diverse populations is not established.
Reported adverse signals to watch in research: edema, appetite/weight changes, glucose/insulin shifts (MK-677), and injection-site issues (ipamorelin).
Not medical advice. Human use outside approved trials/regulatory pathways can carry legal and health risks.
References
[1]“CAS Common Chemistry,” Apr. 15, 2021. https://commonchemistry.cas.org/detail?cas_rn=1596... (accessed Apr. 15, 2021).
[2]E. Adeghate and A. S. Ponery, “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004.
[3]J. Svensson et al., “Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males,” J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res., vol. 13, no. 7, Art. no. 7, Jul. 1998, doi: 10.1359/jbmr.1998.13.7.1158.
[4]M. G. Murphy et al., “Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group,” J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res., vol. 14, no. 7, Art. no. 7, Jul. 1999, doi: 10.1359/jbmr.1999.14.7.1182.
[5]A. Adunsky et al., “MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study,” Arch. Gerontol. Geriatr., vol. 53, no. 2, Art. no. 2, Oct. 2011, doi: 10.1016/j.archger.2010.10.004.
[6]J. Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, pp. 569–77, Jul. 2000.
[7]N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund, “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats,” Growth Horm. IGF Res., vol. 11, no. 5, Art. no. 5, Oct. 2001, doi: 10.1054/ghir.2001.0239.
[8]G. Copinschi et al., “Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man,” Neuroendocrinology, vol. 66, no. 4, Art. no. 4, Oct. 1997, doi: 10.1159/000127249.
[9]Y.-O. Jeong et al., “MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer’s Disease,” Int. J. Mol. Sci., vol. 19, no. 6, Art. no. 6, Jun. 2018, doi: 10.3390/ijms19061800.